PETMED EXPRESS INC financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data PETMED EXPRESS INC files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
Revenue	249	274	283	284	304	272	257	281	227	179
Cost of revenue	170	176	188	203	219	195	171	189	158
Gross profit	79.3	97.8	95.3	81.2	84.3	76.9	76.5	84.8	69.1	50.2
General and administrative	22.8	24.3	24.8	25.3	29.7	31.1	41.7	55.2	38.6	50.7
Operating expenses	41.8	45.7	49.1	50.3	53.8	52.7	70.5	92.9	70.7	109
Operating income	37.5	52.1	46.2	31	30.5	24.3	6.05	-8.16	-1.53	-58.7
Interest income	0.14	0.66	1.86	1.75	0.31	0.34	2.07
Other non-operating income	0.44	1.65	2.95	2.92	0.42	-0.11	1.39	1.89	0.94	1.31
Pre-tax income	37.9	53.8	49.1	33.9	31	24.2	7.45	-6.27	-0.59	-57.4
Income tax	14.1	16.5	11.4	8.04	7.03	5.47	2.31	1.19	5.68	-0.07
Net income	23.8	37.3	37.7	25.9	23.9	18.7	5.14	-7.46	-6.27	-57.3
EBITDA	38.9	54.3	48.4	33.2	33	27	9.6	-1.11	5.51	-49.3
EPS, basic	0.92	1.43	1.44	1.01	1.19	0.93	0.25	-0.37	-0.30	-2.74
EPS, diluted	0.92	1.42	1.44	1.01	1.19	0.92	0.25	-0.37	-0.30	-2.74
Shares, basic (weighted)	25.8	26	26.1	25.6	20.1	20.2	20.3	20.4	20.6	20.9
Shares, diluted (weighted)	26	26.1	26.2	25.6	20.1	20.4	20.3	20.4	20.6	20.9
Dividend per share	0.60	0.67	0.83	0.85	1.12	1.20	1.20	0.60	0.00	0.00

Balance sheet

	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
Cash and equivalents	58.7	77.9	101	104	119	111	104	55.3	54.7	21.4
Receivables	1.81	2.29	2.54	3.84	2.59	1.91	1.74	3.28	2.32	1.91
Inventory								28.6	16.2	13.6
Other current assets	1.02	0.88	1.41	3.53	4.5	4.87	4.72	6.33	5.33	6.38
Total current assets	81.8	105	126	129	161	151	130	93.6	78.9	43.6
Property, plant and equipment	30.2	28.7	27.1	25.4	25.5	24.5	26.2	26.7	28.9	26.3
Lease right-of-use assets							0	1.43	0.97	0.51
Goodwill							0	26.7	26.7	0
Intangible assets	0.86	0.86	0.86	0.86	0.86	0.86	0.86	11.2	8.05	5.49
Total assets	113	135	154	155	187	180	167	170	149	81.2
Accounts payable	15.2	15.3	16.3	19.7	39.5	27.5	25.2	37	23.6	20.9
Deferred revenue							0	2.6	2.09	0.69
Total current liabilities	18.4	18.1	18.6	24.3	44.9	56.2	57.5	72.2	62.8	52
Lease liabilities							0	1	0.54	0.04
Other non-current liabilities						0	0
Total liabilities	19.4	19.1	19.7	25.3	46.2	56.2	57.5	73.2	63.6	52.3
Paid-in capital	6.81	9.38	12.5	3.8	7.11	11.7	18.3	25.1	18.6	19.6
Retained earnings	86.5	106	122	126	134	112	91.7	71.6	66.5	9.26
Shareholders' equity	93.4	116	135	120	125	123	110	96.7	85.1	28.9
Total equity	93.4	116	135	120	125	123	110	96.7	85.1	28.9
Total liabilities and equity	113	135	154	155	187	180	167	170	149	81.2
Shares outstanding	26.2	26.3	26.4	25.8	20.3	21	21.1	21.1	20.7	21.4

Cash flow statement

	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
Net income	23.8	37.3	37.7	25.9	23.9	18.7	5.14	-7.46	-6.27	-57.3
Depreciation and amortization	1.37	2.13	2.23	2.26	2.43	2.74	3.55	7.06	7.04	9.39
Stock-based compensation	1.94	2.58	3.1	2.82	3.31	4.55	6.62	6.87	-6.59	1.37
Deferred income tax	1.95	-0.09	0.13	-0.15	-1.27	-0.85	-1.63	0.29	5.25	-0.09
Change in receivables	-0.51	-0.6	-0.34	-1.49	1.13	0.51	-0.04	-1.74	0.6	0.45
Change in inventory							13.4	-6.42	12.4	0.47
Change in payables	10.2	0.05	1	3.38	19.9	-12	-2.29	6.1	-13.5	-2.66
Cash from operations	47.2	37.4	45.1	38.8	40.1	18.5	27.8	4.32	4.72	-28.4
Capital expenditures	-10.6	-0.7	-0.62	-2.31	-2.43	-1.75	-5.26	-4.51	-5.11	-4.62
Acquisitions						0	0	-35.9	0	0
Cash from investing	-10.6	-0.7	-0.62	-2.31	-2.43	-1.75	-10.3	-40.7	-5.11	-4.62
Share buybacks			0	-11.5	0	0
Dividends paid	-15.5	-17.5	-21.9	-21.8	-22.7	-24.4	-24.5	-12.4	-0.18	-0.02
Cash from financing	-15.5	-17.5	-21.9	-33.3	-22.7	-24.4	-24.5	-12.4	-0.18	-0.3
Net change in cash	21.1	19.2	22.6	3.23	15	-7.64	-6.99	-48.8	-0.58	-33.3
Free cash flow	36.6	36.7	44.5	36.5	37.6	16.7	22.5	-0.19	-0.4	-33
Income taxes paid	11.4	18	11.1	7.14	10	6.09	4.31	0.13	0.53	0.05

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $1.53 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	27.9%	Gross profit / revenue.
Operating margin	-18.2%	Operating income / revenue.
EBITDA margin	-12.7%	EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin	-17.4%	Pre-tax income / revenue.
Net margin	-17.3%	Net income / revenue.
FCF margin	-16.4%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	-14.1%	Cash from operations / revenue.
Return on equity (ROE)	-127.4%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	-45.9%	Net income / average total assets.
Return on invested capital (ROIC)	-245.3%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Stock-based pay / revenue	0.6%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	2.3%	Capital expenditures / revenue.
D&A / revenue	5.5%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	-21.1%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	-11.3%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	-10.0%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	-27.4%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	-13.1%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	-9.8%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EBITDA growth, 1y	-994.6%	EBITDA vs the same period a year earlier. Only from a positive base.
Operating cash flow growth, 1y	-701.8%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Book value growth, 1y	-66.0%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	-35.9%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	-25.4%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	-45.4%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	-21.4%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	-15.4%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	1.6%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	0.9%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	0.8%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	0.68x	Current assets / current liabilities.
Quick ratio	0.36x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	0.32x	(Cash + short-term investments) / current liabilities.
Liabilities / assets	63.9%	Total liabilities / total assets.
Working capital	-$13.0M	Current assets - current liabilities.
Goodwill and intangibles / assets	8.2%	(Goodwill + intangible assets) / total assets.
Tangible book value	$17.7M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	2.65x	Revenue / average total assets.
Fixed asset turnover	6.70x	Revenue / average property, plant and equipment.
Receivables turnover	99.0x	Revenue / average receivables.
Days sales outstanding	4 days	365 x average receivables / revenue.

Per share

Metric	Value	How it is calculated
EPS, diluted	-$1.35	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$7.79	Revenue / diluted weighted shares.
FCF per share	-$1.28	Free cash flow / diluted weighted shares.
Operating cash flow per share	-$1.10	Cash from operations / diluted weighted shares.
Book value per share	$1.06	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	$0.82	Tangible book value / shares outstanding.
Cash per share	$0.60	(Cash + short-term investments) / shares outstanding.

Valuation

Metric	Value	How it is calculated
Market cap	$33.2M	Share price x shares outstanding.
Enterprise value	$20.1M	Market cap + total debt - cash - short-term investments.
P/S	0.20x	Market cap / revenue.
P/B	1.44x	Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book	1.87x	Market cap / tangible book value, when positive.
EV/Sales	0.12x	Enterprise value / revenue.
FCF yield	-83.7%	Free cash flow / market cap.
Earnings yield	-88.3%	Net income / market cap (the inverse of P/E).
Dividend yield	0.1%	Dividends paid over the period / market cap.
Shareholder yield	0.1%	(Dividends paid + share buybacks) / market cap.

What was PETMED EXPRESS INC's revenue in fiscal 2026?

PETMED EXPRESS INC reported revenue of $179.0M for fiscal 2026, 21.1% lower than the year before.

Was PETMED EXPRESS INC profitable in fiscal 2026?

No. It reported a net loss of $57.3M.

How much free cash flow did PETMED EXPRESS INC generate in fiscal 2026?

Cash from operations of $28.4M minus capital expenditures of $4.6M left free cash flow of -$33.0M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to PETMED EXPRESS INC